期刊文献+

人工神经网络用于华法林剂量模型的研究进展

Research progress of artificial neural network in warfarin dosage model
下载PDF
导出
摘要 基于人工神经网络的华法林药物剂量预测模型利用神经网络对于非线性函数的拟合能力,对华法林服用者的数据进行训练,以此建立的模型能够为服用华法林进行抗凝治疗的患者预测起始或维持剂量,有助于减少服药者抗凝不足造成栓塞或抗凝过度导致出血的风险。根据近年神经网络华法林药物剂量预测模型的研究进展进行归纳评述,并对神经网络及人工智能用于医疗的前景进行展望。 The prediction model of warfarin drug dose based on artificial neural network uses the fitting ability of neural network to nonlinear function to train the data of warfarin users.The established model can predict the initial or maintenance dose of patients taking warfarin for anticoagulation treatment,which is helpful to reduce the risk of embolism due to insufficient anticoagulation or bleeding due to excessive anticoagulation in patients taking warfarin.According to the research progress of neural network-warfarin drug dose prediction model in recent years,the prospect of neural network and artificial intelligence used in medical treatment is prospected.
作者 毛德龙(综述) 庄文芳(审校) MAO Delong;ZHUANG Wenfang(School of Health Science and Engineering,University of Shanghai for Science and Technology,Shanghai 200093,China;Department of Clinical Laboratory,Shidong Hospital Affiliated to University of Shanghai for Science and Technology,Shanghai 200438,China)
出处 《国际检验医学杂志》 CAS 2023年第6期740-744,共5页 International Journal of Laboratory Medicine
基金 上海市杨浦区医学重点学科基金(YP19ZB03)。
关键词 人工智能 人工神经网络 华法林 药物模型 artificial intelligence artificial neural network warfarin drug model
  • 相关文献

参考文献4

二级参考文献40

  • 1张冬妍,郎奕.华法林与148种药物相互作用分析[J].中国城乡企业卫生,2006,21(6):46-47. 被引量:2
  • 2姚均迪,蒋逸风,赵峰,陆传新,扬扬,唐可,赵宏坤,林晓耘.胺碘酮增强华法林钠的抗凝作用[J].临床荟萃,2006,21(11):810-811. 被引量:8
  • 3杨扬,姚均迪,林晓耘.胺碘酮与华法林的相互作用[J].海军医学杂志,2006,27(3):269-271. 被引量:18
  • 4田建英,宋霄.不同剂量乙胺碘呋酮维持老年房颤患者复律后窦性心律的疗效观察[J].中国老年学杂志,2006,26(10):1408-1409. 被引量:3
  • 5Hirsh J, Fuster V, Ansell J,et al. American HeartAssociation/ American College of CardiologyFoundation guide to warfarin therapy [ J ]. J Am CollCardiol, 2003,41(9) : 1633-1652.
  • 6Wadelius M, Chen LY, Lindh JD, et al. The largestprospective warfarin-treated cohort supports geneticforecasting!] J]. Blood, 2009 , 113(4):784-792.
  • 7Fumy a H,Fernandez-Salguero P, Gregory W, et al.Genetic polymorphism of CYP2C9 and its effect onwarfarin maintenance dose requirement in patientsundergoing anticoagulation therapy [ J ].Pharmacogenetics, 1995 , 5(6) :389-392.
  • 8Avery PJ, Jorgensen A, Hamberg AK, et al. A proposalfor an individualized pharmacogenetics-based warfarininitiation dose regimen for patients commencinganticoagulation therapy [ J ]. Clin Pharmacol Ther,2011, 90(5) :701-706.
  • 9Rost S,Fregin A, Ivaskevicius V,et al. Mutations inVKORC1 cause warfarin resistance and multiplecoagulation factor deficiency type 2 [ J ]. Nature,2004,427(6974) :537-541.
  • 10D;Andrea G, D'Ambrosio RL, Di Pema P, et al. Apolymorphism in the VKORCl gene is associated withan interindividual variability in the dose-anticoagulanteffect of warfarin [ J ]. Blood,2005 , 105 ( 2 ) : 645-649.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部